Avacta Group PLC (GB:AVCT)

LSE:AVCT

AVCT

Avacta Group plc

RESEARCH TOOLSreports

Want to see GB:AVCT full AI Analyst Report?

Avacta Group plc (AVCT) Price & Analysis

79 Followers

AVCT Stock Chart & Stats

65.00 p

-0.10 p(-0.19%)

At close: Jan 09 4:00 PM EST

65.00 p

-0.10 p(-0.19%)

Day’s Range― - ―

52-Week Range28.00 p - 92.00 p

Previous CloseN/A

Volume371.99K

Average Volume (3M)3.07M

Market Cap

£328.05M

Enterprise Value343.61M

Total Cash (Recent Filing)£16.86M

Total Debt (Recent Filing)£14.92M

Price to Earnings (P/E)―

Beta0.90

Next Earnings

Oct 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding440,415,500

10 Day Avg. Volume4,236,507

30 Day Avg. Volume3,069,625

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)93.68

Price to Sales (P/S)2052.69

P/FCF Ratio-9.35

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.06

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Preclinical Differentiation Vs ADCsMaterial preclinical advantages (much higher tumor Cmax and improved tumor:plasma selectivity) represent a durable technical moat. If translated clinically, this can materially improve therapeutic index, lower off-target toxicity, and make Avacta's platform more attractive to partners across many solid tumor indications.

On-time Clinical ExecutionConsistent, on-schedule execution of first-in-human dosing and multicenter US enrollment signals operational strength. Reliable trial execution reduces timeline risk, enhances credibility with potential partners, and supports milestone-triggered revenues and licensing discussions over the medium term.

Strengthened IP & Dual-payload CapabilityAn expanding IP estate and unique dual-payload technology create a defensible competitive position. These durable assets can underpin licensing, partnerships, and barriers to competition, increasing the company's strategic leverage during partner negotiations and supporting long-term revenue streams if clinical proof is achieved.

Bears Say

Weak Cash Flow & Shrinking Balance SheetPersistent negative operating and free cash flows, combined with a materially reduced equity base and asset shrinkage, constrain financial flexibility. Limited runway increases dependency on external funding or partnering and raises execution and dilution risk for multi-year clinical programs.

Dependence On Partners For Pivotal DevelopmentRequiring a partnering agreement before pivotal trials introduces structural timeline and execution risk. This dependency limits Avacta's control over development pace and commercial economics, potentially delaying value inflection points and reducing capture of downstream royalties or sales value.

AVA6000 Dose Tolerability UncertaintyOngoing tolerability issues and unresolved final dose selection create persistent clinical risk. Dose constraints can reduce efficacy potential or require longer development, increasing costs and complicating partner discussions; this can materially affect long-term commercial viability of the program.

Avacta Group plc News

Avacta applies for AIM block listing to cover employee share options

Avacta Group plc ( ($GB:AVCT) ) just unveiled an update. Avacta has applied for a block listing of...

2d ago

Avacta Reports Strong Early Efficacy and Cardiac Safety for AVA6000 in Salivary Gland Cancer

The latest update is out from Avacta Group plc ( ($GB:AVCT) ). Avacta Therapeutics has reported updated Phase...

3d ago

Avacta reshapes board leadership as oncology pipeline advances

The latest announcement is out from Avacta Group plc ( ($GB:AVCT) ). Avacta Therapeutics has announced that non-executive...

6d ago

Avacta publishes 2025 annual report and sets June AGM with online business update

The latest announcement is out from Avacta Group plc ( ($GB:AVCT) ). Avacta Therapeutics has published its Annual...

6d ago

Avacta Earnings Call: Clinical Progress Amid Funding Risks

Avacta Group plc (($GB:AVCT)) has held its Q4 earnings call. Read on for the main highlights of the...

8d ago

Avacta advances pre|CISION oncology pipeline and extends cash runway into 2027

Avacta Group plc ( ($GB:AVCT) ) has shared an announcement. Avacta reported significant R&D progress in 2025, advancing...

16d ago

Avacta Cuts Convertible Debt with New Share Issue on AIM

Avacta Group plc ( ($GB:AVCT) ) just unveiled an announcement. Avacta Group plc, a clinical-stage biopharmaceutical company specializing...

22d ago

Avacta Sets Date for FY25 Results and Investor Presentation

Avacta Group plc ( ($GB:AVCT) ) just unveiled an announcement. Avacta Therapeutics, a clinical-stage biopharmaceutical arm of Avacta...

22d ago

Avacta Showcases Pre|CISION Platform Data Beating Leading ADCs at 2026 Science Day

Avacta Group plc ( ($GB:AVCT) ) has issued an update. Avacta Group’s oncology-focused Avacta Therapeutics unit is advancing...

29d ago

Avacta Files Six‑Monthly Block Listing Update for Employee Share Schemes

Avacta Group plc ( ($GB:AVCT) ) has shared an announcement. Avacta Group plc has reported its latest six‑monthly...

1M ago

AVCT FAQ

What was Avacta Group PLC’s price range in the past 12 months?

Avacta Group PLC lowest share price was 28.00 p and its highest was 92.00 p in the past 12 months.

What is Avacta Group PLC’s market cap?

Avacta Group PLC’s market cap is £328.05M.

When is Avacta Group PLC’s upcoming earnings report date?

Avacta Group PLC’s upcoming earnings report date is Oct 05, 2026 which is in 124 days.

How were Avacta Group PLC’s earnings last quarter?

Avacta Group PLC released its earnings results on May 19, 2026. The company reported -0.051 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.051 p.

Is Avacta Group PLC overvalued?

According to Wall Street analysts Avacta Group PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Avacta Group PLC pay dividends?

Avacta Group PLC does not currently pay dividends.

What is Avacta Group PLC’s EPS estimate?

Avacta Group PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Avacta Group PLC have?

Avacta Group PLC has 440,415,500 shares outstanding.

What happened to Avacta Group PLC’s price movement after its last earnings report?

Avacta Group PLC reported an EPS of -0.051 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.959%.

Which hedge fund is a major shareholder of Avacta Group PLC?

Currently, no hedge funds are holding shares in GB:AVCT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Avacta Group plc Stock Smart Score

Outperform

Company Description

Avacta Group PLC

Avacta Group plc is a biotechnology company based in the UK that focuses on developing innovative therapies and diagnostics for various diseases, including cancer. The company operates primarily in the life sciences sector, utilizing its proprietary Affimer technology, which is a platform for the development of therapeutic and diagnostic products. Avacta's core offerings include Affimer proteins that can be used for both research and therapeutic applications, as well as its development of a novel cancer immunotherapy and diagnostic tests for COVID-19 and other diseases.